Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| Nectin-4 | 80-90% | IHC, moderate-strong | Wikipedia |
| TROP2 | 80-90% | IHC, any expression | PMC |
| PD-L1 | 25-30% | CPS >=10 | Wikipedia |
| FGFR2 FGFR3 mutations/fusions; erdafitinib | 15-20% | FGFR3 alterations (related target) | cBioPortal (TCGA) |
| FGFR3 The BLC2001 trial of erdafitinib enrolled patients with these alterations, which its report describes as present in roughly a fifth of advanced urothelial carcinomas. | 15-20% | FGFR3 mutation or FGFR2/3 fusion in advanced urothelial carcinoma | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
6 cell lines, 2 mouse models and 6 repositories are listed for this cancer. See them →